Abstract: The present invention provides new adeno-associated virus (AAV) viruses and vectors, and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV vectors and particles.
Type:
Grant
Filed:
May 1, 2006
Date of Patent:
October 9, 2012
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: The invention provides a recombinant rabies viruses comprising three copies of a mutated G gene wherein each G gene encodes a rabies virus glycoprotein having the amino acid 194 mutated to a serine and the amino acid 333 is mutated to a glutamic acid. The recombinant rabies virus is nonpathogenic in immunodeficient mammals and can be used in a vaccine to induce an immune response protect mammals from infection by rabies virus as well as clear a pre-existing rabies virus infection from neural tissues.
Type:
Grant
Filed:
September 10, 2010
Date of Patent:
October 9, 2012
Assignee:
Thomas Jefferson University
Inventors:
Milosz Faber, Bernhard Dietzschold, Douglas Craig Hooper
Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
Type:
Grant
Filed:
May 12, 2010
Date of Patent:
September 25, 2012
Assignee:
Trellis RSV Holdings, Inc.
Inventors:
Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.
Type:
Grant
Filed:
October 5, 2007
Date of Patent:
September 25, 2012
Assignee:
Melbourne Health
Inventors:
Angeline Bartholomeusz, Margaret Littlejohn, Anna Ayres, Stephen Locarnini
Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebulizer. Also provided is IFN-? for the same purpose.
Type:
Grant
Filed:
June 18, 2009
Date of Patent:
September 25, 2012
Assignee:
University of Southampton
Inventors:
Donna Elizabeth Davies, Peter Alexander Blanch Wark, Stephen Holgate, Sebastian L. Johnston
Abstract: Disclosed herein are vaccine compositions comprising live attenuated virus with anti-antibody to improve efficacy. Specifically exemplified herein is a composition comprising live attenuated cold adapted influenza virus and an enhancing amount of IgG anti-IgA antibody to temporarily inactivate IgA defenses. Also disclosed herein are methods of immunizing a subject to protect against influenza comprising administering compositions taught herein.
Type:
Grant
Filed:
March 19, 2008
Date of Patent:
September 18, 2012
Assignee:
University of Florida Research Foundation, Inc.
Inventors:
Parker A. Small, Jr., Bradley S. Bender
Abstract: The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.
Abstract: The invention relates to the methods and kits comprising modified vaccinia virus Ankara (MVA) to provide immediate protection against pathogens. MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.
Abstract: The invention concerns compositions and methods for preparing recombinant adenoviruses. The resulting adenoviruses can be used for transferring and/or expressing genes in cells, in vitro, ex vivo or in vivo, or also in functional genomics. More particularly, the invention concerns in particular efficient methods for producing adenovirus banks and the use of said banks in functional genomics. The invention also concerns plasmids used for constructing said adenoviruses.
Abstract: The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
Type:
Grant
Filed:
September 12, 2007
Date of Patent:
September 11, 2012
Assignee:
AlphaVax, Inc.
Inventors:
Jonathan F. Smith, Bolyn Hubby, Peter Berglund, Laura Copp, Whitney Ellis
Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
Abstract: An antiviral vaccine that encodes costimulation molecules for increasing immune response to the particular virus at issue is provided herein. In an illustrative embodiment, in mice lacking both B7-1 and B7-2 (B7KO), the increased severity of HSV infection has confirmed the importance of these molecules in generation of HSV-specific immunity. To test the concept that B7-1 or B7-2 expression by replication-defective HSV could augment its immunogenicity and protective capacity, the present inventors constructed replication-defective HSV-2 encoding B7-1 or B7-2. Both viruses partially reconstituted immune responses to HSV compared with replication-defective virus alone when used to immunize B7KO mice, indicating that the increased responsiveness to virus could be attributed to virus-encoded B7 molecules.
Type:
Grant
Filed:
July 3, 2009
Date of Patent:
September 4, 2012
Assignee:
Saint Louis University
Inventors:
Lynda A. Morrison, Lydia G. Thebeau, Jane E. Schrimpf
Abstract: The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins.
Type:
Grant
Filed:
November 2, 2007
Date of Patent:
August 14, 2012
Assignee:
The United States of America as represented by the Secretary of the Navy
Abstract: The present invention relates to oncolytic Picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation.
Type:
Grant
Filed:
August 22, 2005
Date of Patent:
August 7, 2012
Assignee:
Viralytics Limited
Inventors:
Gough Geoffrey Au, Darren Raymond Shafren
Abstract: Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line CmA40 as deposited under American Type Culture Collection patent deposit number PTA-11304 is produced by cell fusion of a parental cell and a myeloma cell line. The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line CmA40 as deposited under American Type Culture Collection patent deposit number PTA-11304 can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.
Type:
Grant
Filed:
July 13, 2010
Date of Patent:
July 31, 2012
Assignee:
Animal Health Research Institute, Council of Agriculture, Executive Yuan
Inventors:
Tsu-Han Chen, Fan Lee, Chu-Hsiang Pan, Ming-Hwa Jong
Abstract: The present invention relates to methods for purification of Vaccinia viruses (W) and/or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.
Abstract: Disclosed are compositions and methods relating to growth of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using non-simian cells. In a particular example, porcine alveolar macrophage cells are described as having a capability of supporting infectivity and reproduction by PRRSV. Cells and cell lines of the invention are disclosed in connection with applications relating to PRRS disease, including vaccine technologies.
Type:
Grant
Filed:
January 11, 2008
Date of Patent:
June 19, 2012
Assignee:
The Board of Trustees of the University of Illinois
Abstract: The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
Abstract: The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections.
Type:
Grant
Filed:
June 30, 2008
Date of Patent:
June 19, 2012
Assignee:
Ribovax Biotechnologies S.A.
Inventors:
Ada Funaro, Giorgio Gribaudo, Santo Landolfo
Abstract: An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to affect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA.
Type:
Grant
Filed:
October 17, 2007
Date of Patent:
September 11, 2012
Assignee:
Bayer HealthCare LLC
Inventors:
Wytold R. Lebing, Douglas C. Lee, Klaus-Peter Radtke, Scott A. Cook, Hanns-Ingolf Paul, Patricia Alred